FDA Approves Eydenzelt (aflibercept-boav), a Biosimilar to Eylea

Oct 10, 2025 - 15:00
 0  1
INCHEON, South Korea, Oct. 9, 2025 /PRNewswire/ -- Celltrion, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved Eydenzelt (aflibercept-boav), biosimilar referencing Eylea (aflibercept), for the treatment of...

What's Your Reaction?

Like Like 0
Dislike Dislike 0
Love Love 0
Funny Funny 0
Angry Angry 0
Sad Sad 0
Wow Wow 0